SI1849773T1 - Piperazinski derivati za zdravljenje urinske inkontinence in bolečine - Google Patents

Piperazinski derivati za zdravljenje urinske inkontinence in bolečine

Info

Publication number
SI1849773T1
SI1849773T1 SI200631681T SI200631681T SI1849773T1 SI 1849773 T1 SI1849773 T1 SI 1849773T1 SI 200631681 T SI200631681 T SI 200631681T SI 200631681 T SI200631681 T SI 200631681T SI 1849773 T1 SI1849773 T1 SI 1849773T1
Authority
SI
Slovenia
Prior art keywords
pain
treatment
urinary incontinence
piperazine derivatives
piperazine
Prior art date
Application number
SI200631681T
Other languages
English (en)
Slovenian (sl)
Inventor
Takahiro Ishii
Takashi Sugane
Jun Maeda
Fumie Narazaki
Akio Kakefuda
Kentaro Sato
Tatsuhisa Takahashi
Takatoshi Kanayama
Chikashi Saitoh
Jotaro Suzuki
Chisato Kanai
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Publication of SI1849773T1 publication Critical patent/SI1849773T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
SI200631681T 2005-02-17 2006-02-16 Piperazinski derivati za zdravljenje urinske inkontinence in bolečine SI1849773T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2005040197 2005-02-17
JP2005303065 2005-10-18
PCT/JP2006/302698 WO2006088075A1 (ja) 2005-02-17 2006-02-16 ピリジル 非芳香族含窒素ヘテロ環－１－カルボン酸エステル誘導体
EP06713839.6A EP1849773B1 (en) 2005-02-17 2006-02-16 Piperazine derivatives for the treatment of urinary incontinence and pain

Publications (1)

Publication Number Publication Date
SI1849773T1 true SI1849773T1 (sl) 2013-12-31

Family

ID=36916476

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200631681T SI1849773T1 (sl) 2005-02-17 2006-02-16 Piperazinski derivati za zdravljenje urinske inkontinence in bolečine
SI200631896T SI2607362T1 (sl) 2005-02-17 2006-02-16 Piperidinski in piperazinski karboksilati kot FAAH inhibitorji

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200631896T SI2607362T1 (sl) 2005-02-17 2006-02-16 Piperidinski in piperazinski karboksilati kot FAAH inhibitorji

Country Status (20)

Country Link
US (3) US7919495B2 (enExample)
EP (2) EP1849773B1 (enExample)
JP (1) JP4702361B2 (enExample)
KR (3) KR101065979B1 (enExample)
CN (1) CN101160287B (enExample)
AU (3) AU2006215080B2 (enExample)
BR (1) BRPI0608205B8 (enExample)
CA (1) CA2598294C (enExample)
CY (2) CY1114709T1 (enExample)
DK (2) DK2607362T3 (enExample)
ES (2) ES2433290T3 (enExample)
IL (1) IL184998A (enExample)
MX (1) MX2007010076A (enExample)
NO (1) NO20074697L (enExample)
PL (2) PL2607362T3 (enExample)
PT (2) PT2607362E (enExample)
RU (3) RU2408581C2 (enExample)
SI (2) SI1849773T1 (enExample)
TW (3) TWI385152B (enExample)
WO (1) WO2006088075A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200633990A (en) 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
JP2008545009A (ja) * 2005-06-30 2008-12-11 プロシディオン・リミテッド Ｇｐｃｒアゴニスト
MX2007016545A (es) * 2005-06-30 2008-02-21 Prosidion Ltd Agonistas del receptor acoplado a la proteina g.
US7541359B2 (en) 2005-06-30 2009-06-02 Janssen Pharmaceutica N.V. N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase
JP2009527479A (ja) * 2006-02-17 2009-07-30 アバロン ファーマシューティカルズ，インコーポレイテッド ヒドロキシピペリジン誘導体とその使用
WO2008023720A1 (en) 2006-08-23 2008-02-28 Astellas Pharma Inc. Urea compound or salt thereof
RS20090154A (sr) 2006-10-18 2010-10-31 Pfizer Products Inc. Jedinjenja biaril etra uree
JP5603770B2 (ja) * 2007-05-31 2014-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２受容体拮抗薬およびその使用
PL2195293T3 (pl) 2007-08-22 2014-03-31 Astrazeneca Ab Pochodne cyklopropyloamidu
JP2011516557A (ja) * 2008-04-07 2011-05-26 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｇｐｒ１１９活性のモジュレーターとしての化合物および組成物
WO2009143404A1 (en) * 2008-05-23 2009-11-26 Wyeth Piperazine metabotropic glutamate receptor 5 (mglur5) negative allosteric modulators for anxiety/depression
TWI434842B (zh) * 2008-07-14 2014-04-21 Astellas Pharma Inc Azole compounds
RU2011117927A (ru) 2008-11-06 2012-12-20 Астеллас Фарма Инк. Карбаматное соединение или его соль
DK2379525T3 (en) 2008-12-19 2015-10-19 Boehringer Ingelheim Int Cyclic pyrimidin-4-carboxamides, as CCR2 receptor antagonists for the treatment of inflammation, asthma and COPD
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
NZ599770A (en) 2009-12-17 2014-06-27 Boehringer Ingelheim Int New ccr2 receptor antagonists and uses thereof
US20130150346A1 (en) 2010-01-08 2013-06-13 Quest Ventures Ltd. Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome
MX2012008550A (es) 2010-02-05 2012-09-07 Merck Patent Gmbh Derivados de hetaril-[1, 8]naftiridina.
WO2011102795A1 (en) 2010-02-18 2011-08-25 Astrazeneca Ab New crystalline form of a cyclopropyl benzamide derivative
US20130224151A1 (en) 2010-03-31 2013-08-29 United States Of America Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain
JP2013147430A (ja) * 2010-04-28 2013-08-01 Astellas Pharma Inc 夜間頻尿の予防又は治療剤
TW201206440A (en) * 2010-04-28 2012-02-16 Astellas Pharma Inc Prophylactic or therapeutic agent for diseases associated with pains in urinary organs
EP2569298B1 (en) 2010-05-12 2015-11-25 Boehringer Ingelheim International GmbH Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8946218B2 (en) 2010-05-12 2015-02-03 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011144501A1 (en) 2010-05-17 2011-11-24 Boehringer Ingelheim International Gmbh Ccr2 antagonists and uses thereof
US9018212B2 (en) 2010-05-25 2015-04-28 Boehringer Ingelheim International Gmbh Pyridazine carboxamides as CCR2 receptor antagonists
WO2011151251A1 (en) 2010-06-01 2011-12-08 Boehringer Ingelheim International Gmbh New ccr2 antagonists
JP5786258B2 (ja) 2011-07-15 2015-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規かつ選択的なｃｃｒ２拮抗薬
SG11201500498SA (en) * 2012-07-24 2015-03-30 Bial Portela & Ca Sa Urea compounds and their use as enzyme inhibitors
DE102012018115A1 (de) 2012-09-13 2014-03-13 Matthias Lehr Aryl-N-(arylalkyl)carbamate als Hemmstoffe der Fatty Acid Amide Hydrolase
GB201218084D0 (en) * 2012-10-09 2012-11-21 Univ Aston Novel compounds and methods for use in medicine
HUP1300139A2 (en) 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists
DE102013016573A1 (de) 2013-10-04 2015-04-09 Matthias Lehr 1-Tetrazolylpropan-2-one als Inhibitoren von cytosolischer Phospholipase A2 und Fatty Acid Amide Hydrolase, insbesondere geeignet zur topischen Anwendung
MA41168A (fr) * 2014-12-17 2017-10-24 Acraf Nouveaux composés antibactériens
BR112017028492B1 (pt) 2015-07-02 2023-12-26 Centrexion Therapeutics Corporation Citrato de (4-((3r,4r)-3-metoxitetra-hidro-piran-4- ilamino)piperidin-1-il) (5- metil-6-(((2r, 6s)-6-(p-tolil) tetra-hidro-2h-piran-2-il)metilamino)pirimidin-4-il) metanona, seu uso e seu método de preparação, e composição farmacêutica
CA3056076A1 (en) * 2017-03-13 2018-09-20 Abide Therapeutics, Inc. A substituted-heterocyclic-c(o)o-(substituted pyridin-3-yl)compound and its use as a dual magl and faah inhibitor
MY172113A (en) * 2017-07-05 2019-11-14 Frimline Private Ltd A pharmaceutical composition for neuropathic pain
KR20250057925A (ko) 2018-01-11 2025-04-29 켄타우루스 테라퓨틱스 질병 치료를 위한 디하이드로세라마이드 불포화화효소의 저해제
IL281276B2 (en) 2018-09-13 2025-01-01 Celgene Corp (R)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate, compositions and methods of using the same
EP3917508A4 (en) * 2019-01-28 2022-12-21 Mitochondria Emotion, Inc. EAAT2 ACTIVATORS AND METHODS OF USE THEREOF
AU2020391467A1 (en) 2019-11-29 2022-06-23 Autobahn Therapeutics, Inc. Novel thyromimetics
WO2024072930A1 (en) * 2022-09-30 2024-04-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dopamine d3/d2 receptor partial agonists for the treatment of neuropsychiatric disorders

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200462B (enExample) * 1990-09-27 1993-02-21 Hoechst Roussel Pharma
US5744485A (en) 1994-03-25 1998-04-28 Vertex Pharmaceuticals Incorporated Carbamates and ureas as modifiers of multi-drug resistance
SK282252B6 (sk) 1995-01-11 2001-12-03 Samjin Pharmaceutical Co., Ltd. Piperazínové deriváty a farmaceutický prostriedok s ich obsahom
ATE241600T1 (de) * 1996-06-29 2003-06-15 Samjin Pharm Co Ltd Piperazin-derivate und verfahren zu ihrer herstellung
US5870472A (en) * 1996-11-12 1999-02-09 General Instrument Corporation Dynamic relocation of the service data channel
US5780484A (en) * 1996-11-13 1998-07-14 Vertex Pharmaceuticals Incorporated Methods for stimulating neurite growth with piperidine compounds
BR9907300A (pt) 1998-01-27 2000-10-24 Aventis Pharm Prod Inc Inibidores do fator xa oxoaza-heterociclila substituìdos
BR0009433A (pt) * 1999-04-01 2002-01-15 Pfizer Prod Inc Inibidores de sorbitol desidrogenase
EP1208097B1 (en) 1999-07-28 2009-02-18 Aventis Pharmaceuticals Inc. Substituted oxoazaheterocyclyl compounds
KR20030059290A (ko) 2000-11-30 2003-07-07 화이자 프로덕츠 인코포레이티드 Ｇａｂａ 작용제 및 소르비톨 데하이드로게나제 억제제의혼합물
ES2275808T3 (es) 2001-02-06 2007-06-16 Pfizer Products Inc. Composiciones farmaceuticas para el tratamiento de trastornos del snc y otros trastornos.
WO2003051842A2 (en) 2001-12-14 2003-06-26 Novo Nordisk A/S Compositions decreasing activity of hormone-sensitive lipase
JP2003192659A (ja) 2001-12-26 2003-07-09 Bayer Ag フェニル尿素誘導体
CA2469967A1 (en) 2001-12-26 2003-07-10 Bayer Healthcare Ag Urea derivatives as vr1- antagonists
AU2003210824A1 (en) 2002-02-08 2003-09-02 Bristol-Myers Squibb Company (oxime)carbamoyl fatty acid amide hydrolase inhibitors
FR2843964B1 (fr) 2002-08-29 2004-10-01 Sanofi Synthelabo Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
US7176201B2 (en) 2002-10-07 2007-02-13 The Regents Of The University Of California Modulation of anxiety through blockade of anandamide hydrolysis
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
EP1636207A1 (en) 2003-06-12 2006-03-22 Novo Nordisk A/S Substituted piperidine carbamates for use as inhibitors of hormone sensitive lipase
EP1636187A1 (en) 2003-06-12 2006-03-22 Novo Nordisk A/S Substituted piperazine carbamates for use as inhibitors of hormone sensitive lipase
CN1798735A (zh) 2003-06-12 2006-07-05 诺沃挪第克公司 用作激素敏感性脂肪酶的抑制剂的1－芳基－4－(芳氧基羰基)－哌嗪衍生物
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
FR2864080B1 (fr) 2003-12-23 2006-02-03 Sanofi Synthelabo Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique
FR2865205B1 (fr) 2004-01-16 2006-02-24 Sanofi Synthelabo Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique
FR2866888B1 (fr) 2004-02-26 2006-05-05 Sanofi Synthelabo Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique
FR2866884B1 (fr) 2004-02-26 2007-08-31 Sanofi Synthelabo Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique
EP1882684B1 (en) * 2005-05-19 2014-12-10 Astellas Pharma Inc. Pyrrolidine derivative or salt thereof

Also Published As

Publication number Publication date
TW200940507A (en) 2009-10-01
WO2006088075A1 (ja) 2006-08-24
EP1849773A4 (en) 2011-06-15
CY1116348T1 (el) 2017-02-08
TWI385152B (zh) 2013-02-11
PL2607362T3 (pl) 2015-05-29
US7919494B2 (en) 2011-04-05
AU2006215080B2 (en) 2011-03-10
TWI359140B (enExample) 2012-03-01
JPWO2006088075A1 (ja) 2008-07-03
BRPI0608205B1 (pt) 2019-02-05
BRPI0608205B8 (pt) 2021-05-25
CN101160287B (zh) 2011-08-03
BRPI0608205A2 (pt) 2009-12-01
PL1849773T3 (pl) 2014-03-31
ES2528674T3 (es) 2015-02-11
US20100009972A1 (en) 2010-01-14
IL184998A0 (en) 2007-12-03
DK1849773T3 (da) 2013-11-04
CN101160287A (zh) 2008-04-09
KR101063663B1 (ko) 2011-09-07
AU2010202347A1 (en) 2010-07-01
CY1114709T1 (el) 2016-10-05
AU2006215080A1 (en) 2006-08-24
US7919495B2 (en) 2011-04-05
EP1849773A1 (en) 2007-10-31
RU2007134441A (ru) 2009-03-27
RU2376289C2 (ru) 2009-12-20
SI2607362T1 (sl) 2015-03-31
DK2607362T3 (en) 2015-01-19
AU2010202348B2 (en) 2011-07-21
KR20090077855A (ko) 2009-07-15
RU2009121774A (ru) 2010-09-27
MX2007010076A (es) 2007-10-16
KR101065979B1 (ko) 2011-09-19
AU2010202347B2 (en) 2011-06-02
RU2009121775A (ru) 2010-09-27
JP4702361B2 (ja) 2011-06-15
IL184998A (en) 2014-11-30
KR101063585B1 (ko) 2011-09-07
KR20090078841A (ko) 2009-07-20
RU2408581C2 (ru) 2011-01-10
EP2607362B1 (en) 2014-12-31
US7915261B2 (en) 2011-03-29
KR20070107122A (ko) 2007-11-06
PT1849773E (pt) 2013-12-04
TW200940526A (en) 2009-10-01
CA2598294C (en) 2011-10-18
NO20074697L (no) 2007-11-16
EP2607362A1 (en) 2013-06-26
US20100009971A1 (en) 2010-01-14
TWI385164B (zh) 2013-02-11
TW200640864A (en) 2006-12-01
RU2408580C2 (ru) 2011-01-10
ES2433290T3 (es) 2013-12-10
PT2607362E (pt) 2015-03-16
US20080306046A1 (en) 2008-12-11
EP1849773B1 (en) 2013-10-16
AU2010202348A1 (en) 2010-07-01
CA2598294A1 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
PL1849773T3 (pl) Pochodne piperazyny do leczenia nietrzymania moczu i bólu
EP1827338A4 (en) TREATMENT OF ANAL INCONTINENCE
EP1879578A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE
EP2073752A4 (en) IMPLANTABLE DEVICES FOR THE TREATMENT OF INCONTINENCE, AND METHODS OF USE
PL2436338T3 (pl) Urządzenie do leczenia zwieraczy tkanki ciała i tym podobnych
IL191772A0 (en) Compounds for the treatment of inflammatory disorders and microbial diseases
IL198519A (en) 7 of the 1, 2, 3, 11- tetrahydro-5, 11-diazo-benzo [a] Trindein-4, 6- deion and its derivatives for use as radiation susceptibility factors for cancer treatment
PL369763A1 (en) Heterocyclic compounds for use in the treatment of disorders of the urinary tract
PL1685834T3 (pl) Zastosowanie kwasu pinolenowego do leczenia otyłości
IL180737A0 (en) Arylsulphonylstilbene derivatives for treatment of insomnia and related conditions
IL176968A0 (en) Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
IL187405A0 (en) Methods and compositions for the treatment of pain
ZA200708033B (en) Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia
IL186022A0 (en) Dermatological compositions and salts for the treatment of dermatological diseases
IL178827A0 (en) Use of reboxetine for the treatment of pain
PT1771415E (pt) Derivados de 2-(1h-indolilsulfanil)arilamina para utilização no tratamento de distúrbios afectivos, dor, adhd e incontinência urinária provocada pelo stress
EP1954800A4 (en) COMPOSITION AND USE OF PHYTO-PERCOLATE FOR THE TREATMENT OF DISEASE
EP1933853A4 (en) TREATMENT OF TISSUE DISTRACTION AND COMPOSITION FOR APPLYING THEREOF
EP1928247A4 (en) COMPOSITION AND USE OF PHYTO-PERCOLATE FOR THE TREATMENT OF DISEASE
EP1886631A4 (en) SUB-URETRAL RIBBON FOR THE SURGICAL TREATMENT OF FEMININE URINARY INCONTINENCE AND SURGICAL INSTRUMENTS FOR THE IMPLEMENTATION OF THIS RIBBON
TWI350753B (en) 1-[2h-1-benzopyran-2-one-8-yl]-piperazine derivatives for the treatment of pain
AU2003283153A8 (en) Pharmaceutical compositions for the treatment of urinary incontinence
EP1879519A4 (en) IMPLANTABLE SLINGS FOR TREATING INCONTINENCE AND USE METHOD THEREFOR
ZA200803239B (en) Treatment of stress urinary incontinence and mixed urinary incontinence
ZA200710213B (en) Vaccine composition and methods for the treatment of urinary incontinence